Neoadjuvant chemotherapy for high-grade central osteosarcoma of the extremity: Histologic response to preoperative chemotherapy correlates with histologic subtype of the tumor

Cancer

Volumn 97, Issue 12, 2003, Pages 3068-3075

  Bacci, Gaetano ^a   Bertoni, Franco ^a   Longhi, Alessandra ^a   Ferrari, Stefano ^a   Forni, Cristiana ^a   Biagini, Roberto ^a   Bacchini, Patrizia ^a   Donati, Davide ^a   Manfrini, Marco ^a   Bernini, Gabriella ^b   Lari, Stefano ^a  

^a RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Histologic subtype; Osteosarcoma; Prognosis; Response to chemotherapy

Indexed keywords

CISPLATIN; DOXORUBICIN; IFOSFAMIDE; METHOTREXATE;

ADJUVANT CHEMOTHERAPY; ADOLESCENT; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER SURVIVAL; FEMALE; HISTOLOGY; HUMAN; LIMB; MAJOR CLINICAL STUDY; MALE; OSTEOSARCOMA; PREOPERATIVE PERIOD; PRIORITY JOURNAL; TUMOR CLASSIFICATION;

ADOLESCENT; ANTINEOPLASTIC PROTOCOLS; CHEMOTHERAPY, ADJUVANT; EXTREMITIES; FEMALE; HUMANS; MALE; NEOADJUVANT THERAPY; OSTEOSARCOMA; PREOPERATIVE CARE; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 0038052287     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11456     Document Type: Article

References (32)

1. Mirra JM. Bone tumors. Philadelphia: Lea & Febiger, 1989.
2. Dorfman DH, Czerniak B. Bone tumors. St. Louis: Mosby, 1997.
3. Unni KK. Dahlin's bone tumors: general aspects and data on 11087 cases, 5th edition. Philadelphia: Lippincott-Raven, 1996.
4. Campanacci M. Bone and soft tissue tumors, 2nd edition. New York: Springer Verlag, 1999.
5. Huvos AG. Bone tumors: diagnosis, treatment and prognosis, 42nd edition. Philadelphia: W.B. Saunders, 1991.
6. Schajowicz F, Sobin LH. World Health Organization: international histological classification of tumours. Histological typing of bone tumours. Berlin: Springer Verlag, 1993.
7. Rosen G, Caparros B, Huvos AG, et al. Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer. 1982;49: 1221-1230.
8. Winkler K, Beron G, Kotz R, et al. Neoadjuvant chemotherapy for osteogenic sarcoma: results of a Cooperative German/Austrian study. J Clin Oncol. 1984;2:617-624.
9. Winkler K, Beron G, Delling G, et al. Neoadjuvant chemotherapy of osteosarcoma: results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histological tumor response. J Clin Oncol. 1988;6:329-337.
10. Bacci G, Picci P, Ferrari S, et al. Primary chemotherapy and delayed surgery for nonmetastatic osteosarcoma of the extremities. Results in 164 patients preoperatively treated with high doses of methotrexate followed by cisplatin and doxorubicin. Cancer. 1993;72:3227-3238.
11. Kalifa C, Razafindrakoto H, Vassal G, et al. Chemotherapy in osteogenic sarcoma: the experience of the pediatric department of the Goustave Roussy Institute. Cancer Treat Res. 1993;62:347-349.
12. Benjamin RS, Chawla SP, Carrasco CH, et al. Preoperative chemotherapy for osteosarcoma with intravenous doxorubicin and intra-arterial cis-platinum. Ann Oncol. 1992; 3(Suppl 2):S3-S6.
13. Provisor AJ, Ettinger LJ, Nachman JB, et al. Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children's Cancer Group. J Clin Oncol. 1997;15:76-84.
14. Saeter G, Alvegard TA, Elomaa I, Stenwig AE, Holmstrom T, Solheim OP. Treatment of osteosarcoma of the extremities with the T-10 protocol, with emphasis on the effects of preoperative chemotherapy with single-agent high-dose methotrexate: a Scandinavian Sarcoma Group study. J Clin Oncol. 1991;9:1766-1775.
15. Bielack SS, Kempf-Bielack B, Delling G, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1702 patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocol. J Clin Oncol. 2002;20:776-790.
16. Price CHG. The prognosis of osteosarcoma: an analytical study. Br J Radiol. 1966;39:180-188.
17. Taylor WF, Ivins JC, Pritchard DJ, Dahlin DC, Gilchrist GS, Edmonson JH. Trends and variability in survival among patients with osteosarcoma: a 7-year update. Mayo Clin Proc. 1985;60:91-104.
18. Bentzen SM, Poulsen HS, Kaae S, et al. Prognostic factors in osteosarcomas. A regression analysis. Cancer. 1988;62:194-202.
19. Hudson M, Jaffe MR, Jaffe N, et al. Pediatric osteosarcoma: therapeutic strategies, results, and prognostic factors derived from a 10-year experience. J Clin Oncol. 1990;8:1988-1997.
20. Meyers PA, Heller G, Healey J, et al. Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience. J Clin Oncol. 1992;10:5-15.
21. Bacci G, Picci P, Ferrari S, et al. Prognostic significance of serum alkaline phosphatase measurements in patients with osteosarcoma treated with adjuvant or neoadjuvant chemotherapy. Cancer. 1993;71:1224-1230.
22. Bacci G, Ferrari S, Longhi A, et al. High dose ifosfamide in combination with high dose methotrexate, doxorubicin and cisplatin in the neoadjuvant treatment of extremity osteosarcoma: preliminary results of an Italian Sarcoma Group/Scandinavian Sarcoma Group pilot study. J Chemother. 2002;14:198-206.
23. Davis AM, Bell RS, Goodwin PJ. Prognostic factors in osteosarcoma: a critical review. J Clin Oncol. 1994;12:423-431.
24. Ferrari S, Bertoni F, Mercuri M, et al. Predictive factors of disease-free survival for non-metastatic osteosarcoma of the extremity: an analysis of 300 patients treated at the Rizzoli Institute. Ann Oncol. 2001;12:1145-1150.
25. Hauben EI, Weeden S, Pringle J, Van Marck EA, Hogendoorn PC. Does the histological subtype of high-grade central osteosarcoma influence the response to treatment with chemotherapy and does it affect overall survival? A study on 570 patients of two consecutive trials of the European Osteosarcoma Intergroup. Eur J Cancer. 2002;38:1218-1225.
26. Gobel V, Jurgens H, Etspuler G, et al. Prognostic significance of tumor volume in localized Ewing's sarcoma of bone in children and adolescents. J Cancer Res Clin Oncol. 1987;113: 187-191.
27. Bacci G, Ferrari S, Mercuri M, et al. Neoadjuvant chemotherapy for extremity osteosarcoma. Preliminary results of the Rizzoli's 4th study. Acta Oncol. 1998;37:41-48.
28. Ferrari S, Mercuri M, Picci P, et al. Nonmetastatic osteosarcoma of the extremity: results of a neoadjuvant chemotherapy protocol (IOR/OS-3) with high-dose methotrexate, intraarterial or intravenous cisplatin, doxorubicin, and salvage chemotherapy based on histologic tumor response. Tumori. 1999;85:458-464.
29. Bacci G, Ferrari S, Bertoni F, et al. Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at Istituto Ortopedico Rizzoli according to the Istituto Ortopedico Rizzoli/Osteosarcoma-2 protocol: an updated report. J Clin Oncol. 2000;18:4016-4027.
30. Picci P, Bacci G, Campanacci M, et al. Histologic evaluation of necrosis in osteosarcoma induced by chemotherapy. Regional mapping of viable and nonviable tumor. Cancer. 1985;56:1515-1521.
31. Dahlin DC, Unni KK. Osteosarcoma of bone and its important recognizable varieties. Am J Surg Pathol. 1977;1:61-72.
32. Bacci G, Ferrari S, Delepine N, et al. Predictive factors of histologic response to primary chemotherapy in osteosarcoma of the extremity: study of 272 patients preoperatively treated with high-dose methotrexate, doxorubicin, and cisplatin. J Clin Oncol. 1998;16:658-663.